Investors Urged to Join Class Action Against LifeMD, Inc. by October 27, 2025

Class Action Lawsuit Against LifeMD, Inc.: Join Now

Berger Montague, a national plaintiffs' law firm based in Philadelphia, has recently launched a class action lawsuit targeting LifeMD, Inc. (NASDAQ: LFMD). This litigation comes on behalf of investors who acquired LifeMD shares during a specified period from May 7, 2025, to August 5, 2025. Investors who wish to get involved in this legal action have until October 27, 2025, to apply as lead plaintiffs in the case.

The Background of the Case

LifeMD is a company headquartered in New York that specializes in virtual medical services and prescription delivery. The lawsuit alleges that LifeMD misled investors by inflating its competitive advantage in the market and providing unrealistic financial forecasts for 2025.

Specifically, the complaint asserts that the company failed to disclose serious issues regarding escalating customer acquisition costs associated with its RexMD platform. Additionally, the lawsuit points out that LifeMD was actively promoting obesity medications, including Wegovy and Zepbound, without transparently addressing the associated risks and financial implications.

As a result of these alleged misrepresentations, the lawsuit claims that investors were blindsided when the stock value plummeted after the truth was unveiled. The statement made by LifeMD throughout the class period is characterized as materially false or misleading and lacking a reasonable basis, leading to significant financial losses for those who invested during this timeframe.

Implications for Investors

For any investors who are part of LifeMD during the aforementioned class period, taking part as a lead plaintiff in this class action could be a crucial step in seeking justice and potential financial reparations. The legal representation by Berger Montague, which has decades of experience in handling securities class action cases, underscores the seriousness of this litigation.

If you’re a LifeMD investor looking for more information on this class action, you can follow the instructions provided in their official announcement. Individuals wishing to inquire about their rights or the process of joining the lawsuit can reach out to Berger Montague’s representatives, Andrew Abramowitz, Senior Counsel, at [email protected] or call (215) 875-3015, and Caitlin Adorni, Director of Portfolio and Institutional Client Monitoring Services, at [email protected] or (267) 764-4865.

The Role of Berger Montague

Founded in 1970, Berger Montague has established itself as a pioneer in the arena of securities class action lawsuits, advocating for the rights of investors across the United States. The law firm's extensive experience in litigation and commitment to upholding investor rights makes it a key player in this legal battle against LifeMD. The firm has a strong track record of standing up against powerful corporations and providing a voice to individual investors seeking accountability.

In summary, if you are a LifeMD investor, the impending deadline of October 27, 2025, is crucial for you to consider participating in this class action lawsuit. This may be a vital opportunity to reclaim losses related to misleading information disseminated by LifeMD, Inc.